demonstrated that butyrate enhances antitumor immunity by upregulating PD-1 expression on CD8+ T cells, thus improving responses to anti-PD-1 therapy in non-small cell lung cancer. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.